Evidence map›Paper›PMID 38062117›Full record

ArticleNPJ precision oncology2023

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.

Asmerom T Sengal, Vanessa Bonazzi, Deborah Smith, Cristian P Moiola, Rohan Lourie, Rebecca Rogers, Eva Colas, Antonio Gil-Moreno, Sophia Frentzas, Naven Chetty and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Asmerom T SengalEndometrial Cancer Laboratory, School of Biomedical Sciences, Faculty of Health, the Queensland University of Technology located at the Translational Research Institute (TRI), PA Hospital Campus, 37 Kent St Woolloongabba, Brisbane, 4102, QLD, Australia. asmerom.sengal@qut.edu.au.ORCID http://orcid.org/0000-0001-5757-2171
Vanessa BonazziEndometrial Cancer Laboratory, School of Biomedical Sciences, Faculty of Health, the Queensland University of Technology located at the Translational Research Institute (TRI), PA Hospital Campus, 37 Kent St Woolloongabba, Brisbane, 4102, QLD, Australia.ORCID http://orcid.org/0000-0002-2574-0334
Deborah SmithMater Pathology, Mater Health, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-8420-1824
Cristian P MoiolaBiomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), CIBERONC, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7218-0184
Rohan LourieMater Pathology, Mater Health, Brisbane, QLD, Australia.
Rebecca RogersMater Pathology, Mater Health, Brisbane, QLD, Australia.
Eva ColasBiomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), CIBERONC, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0302-4828
Antonio Gil-MorenoBiomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), CIBERONC, 08035, Barcelona, Spain.
Sophia FrentzasDepartment of Medical Oncology, Monash Health, Melbourne, VIC, Australia.
Naven ChettyDepartment of Gynaecologic Oncology, Mater Cancer Centre, Mater Health Services, Brisbane, QLD, Australia.
Lewis PerrinDepartment of Gynaecologic Oncology, Mater Cancer Centre, Mater Health Services, Brisbane, QLD, Australia.
Pamela M PollockEndometrial Cancer Laboratory, School of Biomedical Sciences, Faculty of Health, the Queensland University of Technology located at the Translational Research Institute (TRI), PA Hospital Campus, 37 Kent St Woolloongabba, Brisbane, 4102, QLD, Australia. pamela.pollock@qut.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) patients with metastatic/recurrent disease have limited treatment options and poor survival outcomes. Recently, we discovered the FGFR2c splice isoform is associated with poor prognosis in EC patients. Here we report the establishment of 16 EC patient-derived xenografts (PDX)-derived organoids (PDXOs) with or without FGFR2c expression. In vitro treatment of 5 EC PDXOs with BGJ398 showed significant cell death in 3 models with FGFR2c expression. PDXs with high/moderate FGFR2c expression showed significant tumour growth inhibition (TGI) following 21-day treatment with FGFR inhibitors (BGJ398 or pemigatinib) and significantly prolonged survival in 4/5 models. Pemigatinib + cisplatin combination therapy (n = 5) resulted in significant TGI and prolonged survival in one of two p53abn PDXs. All five models treated with cisplatin alone showed de novo resistance and no survival benefit. Seven-day treatment with BGJ398 revealed a significant reduction in angiogenesis and CD206 + M2 macrophages. These data collectively support the evaluation of FGFR inhibitors in a clinical trial.

Identifiers

PMID38062117
PMCPMC10703877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.